Here, we show that Aloxe3 is activated by the adaptive hepatic fasting response and is itself sufficient to enhance insulin sensitivity, increase basal caloric expenditure, and reduce diet-induced weight gain and fat accumulation, hepatic steatosis, and dyslipidemia. The gene discussed is INS; the disease is metabolic syndrome.